ESC 365 - anti-interleukin-18 as therapy against atherosclerosis

FCVB 2024 Premium Access

anti-interleukin-18 as therapy against atherosclerosis

Session: Novel targets in atherosclerosis

Topic: Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis

Speaker: Professor I. Bot (Leiden, NL)

Event: Frontiers in CardioVascular Biomedicine 2024

Congress Presentation

About the speaker

Professor Ilze Bot

Leiden Academic Center for Drug Research, Leiden (Netherlands (The))

0 follower

3 more presentations in this session

Circulating LIGHT/TNFSF14 levels are negatively associated with cardiovascular mortality, while intra-plaque levels are associated with symptomatic cerebrovascular disease

Speaker: Doctor A. Shami (Malmo, SE)

The calcium-sensing-receptor (CaSR) in adipocytes contributes to sex-differences in the susceptibility to high fat diet induced obesity and atherosclerosis

Speaker: Doctor S. Maas (Aachen, DE)

Human atherosclerotic plaque macrophages associate with clinical presentation and follow diverse lineage differentiation routes

Speaker: Doctor K. Prange (Amsterdam, NL)

Access the full session

Novel targets in atherosclerosis

Speakers: Professor I. Bot, Doctor A. Shami, Doctor S. Maas, Doctor K. Prange

About the event

Frontiers in CardioVascular Biomedicine 2024

12 April - 14 April 2024

Sessions Presentations

Congress

ESC 365 is supported by